SCTX · Scribe Therapeutics, Inc. · Financials
$33.00
+0.86 (+2.68%)
At close · Sep 18
Going-concern doubt
— cleared Sep 2, 2026
The latest filing states the doubt was alleviated.
“Substantial doubt about our ability to continue as a going concern existed as of June 30, 2026 and was alleviated as a result of the completion of our initial public offering and concurrent private placement, which resulted in aggregate net proceeds of approximately $140.7 million.”View the 10-Q filed Sep 2, 2026
Market Cap
$578.48M
Shares
18.93M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
No structured figures reported for this view yet.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.